Gilead Q4 top line up 16%; EPS up 46%; Harvoni sales up 59%; shares up 1% premarket

• Gilead Sciences (NASDAQ:GILD) Q4 results ($M): Total Revenues: 8,506 (+16.3%); Products Sales: 8,409 (+16.4%).
• Net Income: 4,685 (+35.3%); EPS: 3.18 (+45.9%); Non-GAAP EPS: 3.32 (+36.6%).
• Key Product Sales: Harvoni: 3,345 (+58.8%); Sovaldi: 1,547 (-10.7%); Atripla: 800 (-13.5%); Truvada: 936 (+4.3%); Complera/Eviplera: 380 (+9.2%); Stribild: 511 (+32.7%); Viread: 306 (-1.6%).
• 2016 Guidance: Net Product Sales: $30B - 31B.